Trigeminal-Targeted Treatments in Migraine: Is 60% the Magic Number?
Headache
; 59(9): 1659-1661, 2019 10.
Article
en En
| MEDLINE
| ID: mdl-31508812
ABSTRACT
Trigeminal-targeted treatments (TTTs), the most specific and selective therapeutic migraine approach to date, are effective in approximately 60% of patients regardless of treatment type or mechanism, at least if used alone. Sixty percent is also the proportion of migraineurs who develop migraine-like episodes following experimental intravenous administration of trigeminal neuropeptides and roughly 60% is the percentage of patients with a unilateral migraine tracing the area of cutaneous distribution of the trigeminal ophthalmic branch. Hence, mechanisms other than the trigeminovascular activation are probably involved in the 40% of migraineurs who do not respond to TTTs. A closer cooperation between clinical and basic neuroscientists is needed to explore migraine models because only a careful appraisal of migraine endophenotypes may help to unravel their underlying multifaceted pathophysiological machinery.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Enfermedades del Nervio Trigémino
/
Trastornos Migrañosos
Tipo de estudio:
Etiology_studies
Límite:
Humans
Idioma:
En
Revista:
Headache
Año:
2019
Tipo del documento:
Article
País de afiliación:
Italia